NovaBay (NBY) 13D/A: Poplar Point holds 17.52% (1,020,300)
Rhea-AI Filing Summary
Poplar Point Capital and affiliates filed Amendment No. 2 to Schedule 13D on NovaBay Pharmaceuticals (NBY), disclosing beneficial ownership of 1,020,300 shares, representing 17.52% of the common stock. The group reports shared voting and dispositive power over 1,020,300 shares and no sole power.
The amendment notes that NovaBay terminated the voting agreement effective upon the vote, with an Irrevocable Notice of Termination included as an exhibit. The reporting persons state the holding is for investment purposes and, at this time, have no specific plan or proposal to acquire additional or dispose of shares. Poplar Point Capital Management LLC directly holds the 1,020,300 shares, funded from working capital.
Positive
- None.
Negative
- None.
Insights
Stake at 17.52% with voting pact terminated; intentions unchanged.
Poplar Point and affiliates report beneficial ownership of 1,020,300 NovaBay shares, equal to 17.52% of the class, with shared voting and dispositive power and no sole power. PPCM directly holds the shares, sourced from working capital.
The amendment highlights that NovaBay terminated the voting agreement effective upon the vote, removing a coordinated voting arrangement. The reporting group indicates the investment is for portfolio purposes and lists no current plans for additional purchases or dispositions.
Key items to watch are future ownership updates and any new governance arrangements. The Date of Event is 10/15/2025; subsequent disclosures may clarify any changes in intentions or structures.
FAQ
What stake in NovaBay (NBY) does Poplar Point report in this 13D/A?
What changed in governance in this NovaBay (NBY) 13D/A amendment?
What voting and dispositive powers are reported for NovaBay (NBY)?
When is the Date of Event for this NovaBay (NBY) 13D/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.